Premium
Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers
Author(s) -
FANG JING YUAN
Publication year - 2005
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.2005.03807.x
Subject(s) - acetylation , histone deacetylase 5 , histone , cancer research , histone acetyltransferases , hdac11 , medicine , histone deacetylase , hdac10 , histone deacetylase 2 , biochemistry , biology , gene
Histone acetylation regulates gene transcription. Histone acetylation is a reversible process: histone acetyltransferases (HAT) transfer the acetyl moiety from acetyl coenzyme A to the lysine, and histone deacetylases (HDAC) remove the acetyl groups re‐establishing the positive charge in the histones. HDAC inhibitors have antiproliferative activity against human cancer cells via cell cycle arrest, pro‐differentiation, and pro‐apoptosis. In recent years, many studies have shown that specific HDAC inhibitors are helpful for gastrointestinal cancer therapy.